Safety profile of BiTE therapy

Share :
Published: 2 Dec 2021
Views: 270
Dr Arend von Stackelberg - Charité Universitätsmedizin, Berlin, Germany

Dr Arend von Stackelberg speaks to ecancer about a talk he gave at the recent ALL Assembly 2021 meeting on 'safety profile of BiTE therapy'.

He explains how blinatumomab, a type of BiTE (bispecific T-cell engager), functions in the body to destroy leukaemia cells and how adverse events can occur.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.